Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Albendazole

FDA-approved product (tablet, oral), marketed as Albendazole, Albenza.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Albendazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cysticercosis
  • Helminthiasis
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzimidazole derivatives
FDA pharmacologic class
Anthelmintic FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P02CA03; FDA class Anthelmintic

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli35.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis40.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Albendazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Albendazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparative Evaluation of Post Obturation Pain After Root Canal Treatment Using Tricalcium Silicate vs Resin-Based Sealers

    NCT07388368 · start 2026-07-01

    Registered record
    Registry ID
    NCT07388368
    Conditions
    Pain
    Interventions
    Tricalcium silicate sealar; Resin based sealer
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-07-01
    Completion
    2027-01-30
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain
    InterventionTricalcium silicate sealar; Resin based sealer
    PhaseNot applicable
    Registry statusRecruiting

  • Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis

    NCT06376396 · start 2024-06

    Registered record
    Registry ID
    NCT06376396
    Conditions
    Neurocysticercosis
    Interventions
    albendazole and praziquantel; Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2024-06
    Completion
    2026-12
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurocysticercosis
    Interventionalbendazole and praziquantel; Albendazole
    PhasePhase 4
    Registry statusNot yet recruiting

  • The Role of Adjuvant Albendazole After Pulmonary Hydatid Cyst Resection

    NCT06483880 · start 2024-02-01

    Registered record
    Registry ID
    NCT06483880
    Conditions
    Pulmonary Hydatid Cyst
    Interventions
    Albendazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-02-01
    Completion
    2025-07-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Hydatid Cyst
    InterventionAlbendazole; Placebo
    PhaseNot applicable
    Registry statusUnknown

  • Evaluating Impact of Improved Floors on Health

    NCT05914363 · start 2023-04-12

    Registered record
    Registry ID
    NCT05914363
    Conditions
    Diarrhoeal Disease; Hookworm Infection; Ascaris Lumbricoides Infection; Trichuris Infection; Tungiasis
    Interventions
    Sealed washable floor plus behaviour change; Behaviour change intervention; Routine deworming; treatment for tungiasis
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-04-12
    Completion
    2024-09-30
    Enrolment
    2,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiarrhoeal Disease; Hookworm Infection; Ascaris Lumbricoides Infection; Trichuris Infection +1 more
    InterventionSealed washable floor plus behaviour change; Behaviour change intervention; Routine deworming; treatment for tungiasis
    PhaseNot applicable
    Registry statusCompleted

  • Community-based, Controlled, Open-label, Cluster-randomized Trial for the Reduction of Chronic Malnutrition in Children Under Two Years of Age, With Three Intervention Arms Grouped by Clusters, in Two Provinces in Southern Angola, Huíla and Cunene.

    NCT05571280 · start 2022-10-10

    Registered record
    Registry ID
    NCT05571280
    Conditions
    Malnutrition, Child
    Interventions
    Nutritional Supplementation; Money transfers; Standard intervention
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Active not recruiting
    Start
    2022-10-10
    Completion
    2026-07
    Enrolment
    1,423

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalnutrition, Child
    InterventionNutritional Supplementation; Money transfers; Standard intervention
    PhaseNot applicable
    Registry statusActive not recruiting

  • Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Hookworm

    NCT05538767 · start 2022-09-16

    Registered record
    Registry ID
    NCT05538767
    Conditions
    Hookworm Infections
    Interventions
    Emodepside; Albendazole 400mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-09-16
    Completion
    2023-04-11
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHookworm Infections
    InterventionEmodepside; Albendazole 400mg
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva

    NCT05453045 · start 2022-07-18

    Registered record
    Registry ID
    NCT05453045
    Conditions
    Pharmacological Action
    Interventions
    Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-07-18
    Completion
    2022-12-16
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacological Action
    InterventionAlbendazole
    PhaseNot applicable
    Registry statusUnknown

  • The Effectiveness of Albendazole Treatment Among Infected Toxocara Children

    NCT05208333 · start 2022-05

    Registered record
    Registry ID
    NCT05208333
    Conditions
    Toxocara Infection
    Interventions
    Albenza 200Mg Tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-05
    Completion
    2024-03
    Enrolment
    960

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionToxocara Infection
    InterventionAlbenza 200Mg Tablet
    PhaseNot applicable
    Registry statusUnknown

  • Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression

    NCT04738812 · start 2022-04-21

    Registered record
    Registry ID
    NCT04738812
    Conditions
    Tuberculosis; HIV-1-infection; Immuno-Deficiency
    Interventions
    Intensified TB treatment (initial phase); WHO standard TB treatment (initial phase)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-04-21
    Completion
    2025-11-12
    Enrolment
    1,330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; HIV-1-infection; Immuno-Deficiency
    InterventionIntensified TB treatment (initial phase); WHO standard TB treatment (initial phase)
    PhasePhase 3
    Registry statusCompleted

  • Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection

    NCT04913610 · start 2021-05-22

    Registered record
    Registry ID
    NCT04913610
    Conditions
    Onchocerciasis
    Interventions
    ABBV-4083; Placebo for ABBV-4083; Albendazole; Placebo for Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2021-05-22
    Completion
    2023-08-29
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocerciasis
    InterventionABBV-4083; Placebo for ABBV-4083; Albendazole; Placebo for Albendazole
    PhasePhase 2
    Registry statusTerminated

  • Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole

    NCT04311671 · start 2021-05-03

    Registered record
    Registry ID
    NCT04311671
    Conditions
    Onchocerciasis
    Interventions
    Moxidectin; Ivermectin; Albendazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-05-03
    Completion
    2024-09-27
    Enrolment
    12,979

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocerciasis
    InterventionMoxidectin; Ivermectin; Albendazole
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration

    NCT04700423 · start 2021-03-01

    Registered record
    Registry ID
    NCT04700423
    Conditions
    Trichuriasis; Ascariasis; Hookworm Infections; Helminthes; Infestation, Intestinal
    Interventions
    moxidectin (8 mg) / albendazole (400 mg); ivermectin (200 µg/kg) / albendazole (400 mg); ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]; ivermectin (200 µg/kg); moxidectin (8 mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-03-01
    Completion
    2021-09-22
    Enrolment
    536

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrichuriasis; Ascariasis; Hookworm Infections; Helminthes +1 more
    Interventionmoxidectin (8 mg) / albendazole (400 mg); ivermectin (200 µg/kg) / albendazole (400 mg); ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]; ivermectin (200 µg/kg) +1 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Moxidectin for LF, Cote d'Ivoire (DOLF)

    NCT04410406 · start 2020-08-20

    Registered record
    Registry ID
    NCT04410406
    Conditions
    Lymphatic Filariasis
    Interventions
    Ivermectin; Diethylcarbamazine; Albendazole; Moxidectin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-08-20
    Completion
    2024-10-01
    Enrolment
    164

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphatic Filariasis
    InterventionIvermectin; Diethylcarbamazine; Albendazole; Moxidectin
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of IDA for Onchocerciasis

    NCT04188301 · start 2019-12-06

    Registered record
    Registry ID
    NCT04188301
    Conditions
    Onchocerciasis
    Interventions
    IVM w/ ALB; Single dose of IDA; Three daily doses of IDA
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-12-06
    Completion
    2022-06-01
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocerciasis
    InterventionIVM w/ ALB; Single dose of IDA; Three daily doses of IDA
    PhasePhase 2
    Registry statusCompleted

  • Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon

    NCT04326868 · start 2019-11-11

    Registered record
    Registry ID
    NCT04326868
    Conditions
    Helminths Infection; Drug Resistance
    Interventions
    Benzimidazole Anthelmintic
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-11-11
    Completion
    2021-01-30
    Enrolment
    255

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelminths Infection; Drug Resistance
    InterventionBenzimidazole Anthelmintic
    PhasePhase 4
    Registry statusCompleted